Currency In USD
| Previous Close | 4.01 |
| Open | 3.95 |
| Day High | 3.95 |
| Day Low | 3.76 |
| 52-Week High | 7.3 |
| 52-Week Low | 3.46 |
| Volume | 587,963.1 |
| Average Volume | 3.55M |
| Market Cap | 1.25B |
| PE | -9.16 |
| EPS | -0.42 |
| Moving Average 50 Days | 5.06 |
| Moving Average 200 Days | 5.35 |
| Change | -0.16 |
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial eval
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic disease
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
GlobeNewswire Inc.
Oct 16, 2025 8:01 PM GMT
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated